Cannabinoid CB1 receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice

Brain Research

Volumn 1046, Issue 1-2, 2005, Pages 195-206

  González, Sara ^a,c   Mena, María Angeles ^b   Lastres Becker, Isabel ^a,d   Serrano, Alba ^c   De Yébenes, Justo G ^c   Ramos, José A ^a   Fernández Ruiz, Javier ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^d GOETHE UNIVERSITY   (Germany)

Author keywords

Cannabinoid CB1 receptors; Endocannabinoids; Motor inhibition; Parkin; Parkinson's disease

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; DRONABINOL; MESSENGER RNA; PARKIN; RIMONABANT; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CAUDATE NUCLEUS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE EXPRESSION; GENETIC MODEL; HYPERKINESIA; INHIBITION KINETICS; KNOCKOUT MOUSE; MALE; MOTOR ACTIVITY; MOUSE; NERVE CELL NECROSIS; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PUTAMEN; RECEPTOR DENSITY; SUBSTANTIA NIGRA; WILD TYPE;

ANALYSIS OF VARIANCE; ANIMALS; BASAL GANGLIA; DISEASE MODELS, ANIMAL; ENKEPHALINS; FEMALE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; PROTEIN PRECURSORS; RECEPTOR, CANNABINOID, CB1; RNA, MESSENGER; SEX FACTORS; STATISTICS, NONPARAMETRIC; SUBSTANCE P; SUPEROXIDE DISMUTASE; TYROSINE 3-MONOOXYGENASE; UBIQUITIN-PROTEIN LIGASES;

EID: 20144378366     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2005.04.010     Document Type: Article

References (70)

1. L.A. Anderson, J.J. Anderson, T.N. Chase, and J.R. Walters The cannabinoid agonists WIN55,212-2 and CP55,940 attenuate rotational behaviour induced by a dopamine D1 but not D2 agonist in rats with unilateral lesions of the nigrostriatal pathway Brain Res. 691 1995 106 114
2. F. Berrendero, A. Sánchez, A. Cabranes, C. Puerta, J.A. Ramos, A. García-Merino, and J.J. Fernández-Ruiz Changes in cannabinoid CB1 receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis Synapse 41 2001 195 202
3. F. Blandini, G. Nappi, C. Tassorelli, and E. Martignoni Functional changes in the basal ganglia circuitry in Parkinson's disease Prog. Neurobiol. 62 2000 63 88
4. J.M. Brotchie Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease Mov. Disord. 13 1998 871 876
5. J.M. Brotchie The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease Ann. Neurol. 47 2000 S105 S114
6. J.M. Brotchie CB1 cannabinoid receptor signalling in Parkinson's disease Curr. Opin. Pharmacol. 3 2003 54 61
7. A. Carlsson Treatment of Parkinson's with l-DOPA. The early discovery phase, and a comment on current problems J. Neural Transm. 109 2002 777 787
8. K.K. Chung, Y. Zhang, K.L. Lim, Y. Tanaka, H. Huang, J. Gao, C.A. Ross, V.L. Dawson, and T.M. Dawson Parkin ubiquitinates the alpha-synuclein- interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease Nat. Med. 7 2001 1144 1150
9. P. Consroe Brain cannabinoid systems as targets for the therapy of neurological disorders Neurobiol. Dis. 5 1998 534 551
10. T.M. Dawson, and V.L. Dawson Rare genetic mutations shed light on the pathogenesis of Parkinson disease J. Clin. Invest. 111 2003 145 151
11. E.M. Denovan-Wright, and H.A. Robertson Cannabinoid receptor messenger RNA levels decrease in subset neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice Neuroscience 98 2000 705 713
12. V. Di Marzo, M.P. Hill, T. Bisogno, A.R. Crossman, and J.M. Brotchie Enhanced levels of endocannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease FASEB J. 14 2000 1432 1438
13. E. Fernández-Espejo, I. Caraballo, F. Rodríguez de Fonseca, F. El Banoua, B. Ferrer, J.A. Flores, and B. Galán-Rodríguez Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism Neurobiol. Dis. 18 2005 591 601
14. J. Fernández-Ruiz, M. Gomez, M. Hernandez, R. de Miguel, and J.A. Ramos Cannabinoids and gene expression during brain development Neurotox. Res. 6 2004 389 401
15. S.H. Fox, B. Henry, M. Hill, A. Crossman, and J. Brotchie Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease Mov. Disord. 17 2002 1180 1187
16. 9-tetrahydrocannabinol exposure did not alter dopamine transporter and tyrosine hydroxylase mRNA levels in midbrain dopaminergic neurons of adult male and female rats Neurotoxicol. Teratol. 20 1998 549 553
17. C.R. Gerfen The neostriatal mosaic: multiple levels of compartmental organization Trends Neurosci. 15 1992 133 139
18. B.I. Giasson, and V.M. Lee Parkin and the molecular pathways of Parkinson's disease Neuron 31 2001 885 888
19. M. Glass, M. Dragunow, and R.L.M. Faull The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA-A receptor alterations in the human basal ganglia in Huntington's disease Neuroscience 97 2000 505 519
20. M.S. Goldberg, S.M. Fleming, J.J. Palacino, C. Cepeda, H.A. Lam, A. Bhatnagar, E.G. Meloni, N. Wu, L.C. Ackerson, G.J. Klapstein, M. Gajendiran, B.L. Roth, M.F. Chesselet, N.T. Maidment, M.S. Levine, and J. Shen Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons J. Biol. Chem. 278 2003 43628 43635
21. S. González, J. Romero, R. de Miguel, I. Lastres-Becker, M.A. Villanua, A. Makriyannis, J.A. Ramos, and J.J. Fernández-Ruiz Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide Life Sci. 65 1999 327 336
22. P. Gubellini, B. Picconi, M. Bari, N. Battista, P. Calabresi, D. Centonze, G. Bernardi, A. Finazzi-Agro, and M. Maccarrone Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission J. Neurosci. 22 2002 6900 6907
23. M. Herkenham, A.B. Lynn, M.D. Little, L.S. Melvin, M.R. Johnson, D.R. de Costa, and K.C. Rice Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study J. Neurosci. 11 1991 563 583
24. M. Herkenham, A.B. Lynn, B.R. de Costa, and E.K. Richfield Neuronal localization of cannabinoid receptors in the basal ganglia of the rat Brain Res. 547 1991 264 267
25. J.F. Hyde, and T.P. Jerussi Sexual dimorphism in rats with respect to locomotor activity and circling behavior Pharmacol. Biochem. Behav. 18 1983 725 729
26. J.M. Itier, P. Ibañez, M.A. Mena, N. Abbas, C. Cohen-Salmon, G.A. Bohme, M. Laville, J. Pratt, O. Corti, L. Pradier, G. Ret, C. Joubert, M. Periquet, F. Araujo, J. Negroni, M.J. Casarejos, S. Canals, R. Solano, A. Serrano, E. Gallego, M. Sanchez, P. Denefle, J. Benavides, G. Tremp, T.A. Rooney, A. Brice, and J. Garcia de Yebenes Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse Hum. Mol. Genet. 12 2003 2277 2291
27. P. Jenner, and C.W. Olanow Oxidative stress and the pathogenesis of Parkinson's disease Neurology 47 1996 S161 S170
28. H. Kimura, M. Kurimura, M. Wada, T. Kawanami, K. Kurita, Y. Suzuki, T. Katagiri, M. Daimon, T. Kayama, and T. Kato Female preponderance of Parkinson's disease in Japan Neuroepidemiology 21 2002 292 296
29. G. Kunikowska, and P. Jenner 6-Hydroxydopamine-lesioning of the nigrostriatal pathway in rats alters basal ganglia mRNA for copper, zinc- and manganese-superoxide dismutase, but not glutathione peroxidase Brain Res. 922 2001 51 64
30. I. Lastres-Becker, M. Cebeira, M. de Ceballos, B.-Y. Zeng, P. Jenner, J.A. Ramos, and J. Fernández-Ruiz Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets Eur. J. Neurosci. 14 2001 1827 1832
31. 1 receptors in the basal ganglia of a transgenic model of Huntington's disease Brain Res. 929 2002 236 242
32. I. Lastres-Becker, F. Molina-Holgado, J.A. Ramos, R. Mechoulam, and J. Fernández-Ruiz Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease Neurobiol. Dis. 19 2005 96 107
33. A. Lehman Atlas Stereotaxique Du Cerveau de la Souris 1974 Centre National de la Recherche Scientifique Paris
34. O.H. Lowry, N.J. Rosebrough, A.L. Farr, and R.J. Randall Protein measurement with the Folin phenol reagent J. Biol. Chem. 193 1951 265 275
35. K.E. Lyons, J.P. Hubble, A.I. Troster, R. Pahwa, and W.C. Koller Gender differences in Parkinson's disease Clin. Neuropharmacol. 21 1998 118 121
36. M. Maccarrone, P. Gubellini, M. Bari, B. Picconi, N. Battista, D. Centonze, G. Bernardi, A. Finazzi-Agro, and P. Calabresi Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism J. Neurochem. 85 2003 1018 1025
37. P. Mailleux, and J.J. Vanderhaeghen Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study J. Neurochem. 61 1993 1705 1712
38. 9-THC reduces GABA uptake in the globus pallidus Eur. J. Pharmacol. 308 1996 161 164
39. Y.P. Maneuf, A.R. Croosman, and J.M. Brotchie The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease Exp. Neurol. 148 1997 265 270
40. J.P. Meschler, A.C. Howlett, and B.K. Madras Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5, 6-tetrahydropyridine (MPTP)-treated non-human primates Psychopharmacology 156 2001 79 85
41. V. Mesnage, J.L. Houeto, A.M. Bonnet, I. Clavier, I. Arnulf, F. Cattelin, G. Le Fur, P. Damier, M.L. Welter, and Y. Agid Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson's disease Clin. Neuropharmacol. 27 2004 108 110
42. K.R. Müller-Vahl, H. Kolbe, U. Schneider, and H.M. Emrich Cannabis in movement disorders Forsch. Komplement.med. 6 1999 23 27
43. T. Nagatsu, K. Oka, and T. Kato Highly sensitive assay for tyrosine-hydroxylase activity by high-performance liquid chromatography J. Chromatogr. 163 1979 247 252
44. H. Nawa, H. Kotani, and S. Nakanishi Tissue-specific generation of two preprotachykinin mRNAs from one gene by alternative RNA splicing Nature 312 1984 729 734
45. R. Noor, S. Mittal, and J. Iqbal Superoxide dismutase-applications and relevance to human diseases Med. Sci. Monit. 8 2002 RA210 RA215
46. J.J. Palacino, D. Sagi, M.S. Goldberg, S. Krauss, C. Motz, M. Wacker, J. Klose, and J. Shen Mitochondrial dysfunction and oxidative damage in parkin-deficient mice J. Biol. Chem. 279 2004 18614 18622
47. 2 receptors Pharmacol. Ther. 74 1997 129 180
48. C. Pifl, H. Reither, and O. Hornykiewicz Functional sensitization of striatal dopamine D1 receptors in the 6-hydroxydopamine-lesioned rat Brain Res. 572 1992 87 93
49. K. Pong Oxidative stress in neurodegenerative diseases: therapeutic implications for superoxide dismutase mimetics Expert Opin. Biol. Ther. 3 2003 127 139
50. T.A. Reader, and K.M. Dewar Effects of denervation and hyperinnervation on dopamine and serotonin systems in the rat neostriatum: implications for human Parkinson's disease Neurochem. Int. 34 1999 1 21
51. F. Rodriguez de Fonseca, M. Cebeira, J.A. Ramos, M. Martin, and J. Fernandez-Ruiz Cannabinoid receptors in rat brain areas: sexual differences, fluctuations during estrous cycle and changes after gonadectomy and sex steroid replacement Life Sci. 54 1994 159 170
52. J. Romero, R. de Miguel, E. García-Palomero, J. Fernández-Ruiz, and J.A. Ramos Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function Brain Res. 694 1995 223 232
53. J. Romero, R. de Miguel, J.A. Ramos, and J. Fernández-Ruiz The activation of cannabinoid receptors in striatonigral neurons inhibited GABA uptake Life Sci. 62 1998 351 363
54. J. Romero, F. Berrendero, A. Pérez-Rosado, J. Manzanares, A. Rojo, J. Fernández-Ruiz, J.G. de Yébenes, and J.A. Ramos Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen Life Sci. 66 2000 485 494
55. J. Romero, I. Lastres-Becker, R. de Miguel, F. Berrendero, J.A. Ramos, and J. Fernández-Ruiz The endogenous cannabinoid system and the basal ganglia. Biochemical, pharmacological, and therapeutic aspects Pharmacol. Ther. 95 2002 137 152
56. T. Rubino, P. Massi, G. Patrini, I. Venier, G. Giagnoni, and D. Parolaro Chronic CP-55,940 alters cannabinoid receptor mRNA in the rat brain: an in situ hybridization study NeuroReport 5 1994 2493 2496
57. M.C. Sañudo-Peña, S.L. Patrick, S. Khen, R.L. Patrick, K. Tsou, and J.M. Walker Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease Neurosci. Lett. 248 1998 171 174
58. M.C. Sañudo-Peña, K. Tsou, and J.M. Walker Motor actions of cannabinoids in the basal ganglia output nuclei Life Sci. 65 1999 703 713
59. R. Saunders-Pullman Estrogens and Parkinson disease: neuroprotective, symptomatic, neither, or both? Endocrine 21 2003 81 87
60. H. Sawada, and S. Shimohama Estrogens and Parkinson disease: novel approach for neuroprotection Endocrine 21 2003 77 79
61. J.A. Serra, R.O. Dominguez, E.S. de Lustig, E.M. Guareschi, A.L. Famulari, E.L. Bartolome, and E.R. Marschoff Parkinson's disease is associated with oxidative stress: comparison of peripheral antioxidant profiles in living Parkinson's, Alzheimer's and vascular dementia patients J. Neural Transm. 108 2001 1135 1148
62. K.A. Sieradzan, S.H. Fox, M. Hill, J.P. Dick, A.R. Crossman, and J.M. Brotchie Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study Neurology 57 2001 2108 2111
63. M.A. Silverdale, S. McGuire, A. McInnes, A.R. Crossman, and J.M. Brotchie Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease Exp. Neurol. 169 2001 400 406
64. S. Smith, and T. Sharp Measurement of GABA in rat brain microdialysates using o-phtaldialdehyde-sulphite derivatization and high-performance liquid chromatography with electrochemical detection J. Chromatogr. 652 1994 228 233
65. K. Tanaka, T. Suzuki, T. Chiba, H. Shimura, N. Hattori, and Y. Mizuno Parkin is linked to the ubiquitin pathway J. Mol. Med. 79 2001 482 494
66. S.K. Van Den Eeden, C.M. Tanner, A.L. Bernstein, R.D. Fross, A. Leimpeter, D.A. Bloch, and L.M. Nelson Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity Am. J. Epidemiol. 157 2003 1015 1022
67. T. van Laar Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management CNS Drugs 17 2003 475 489
68. K. Venderova, E. Ruzicka, V. Vorisek, and P. Visnovsky Survey on cannabis use in Parkinson's disease: subjective improvement of motor symptoms Mov. Disord. 19 2004 1102 1106
69. W.S. Young, T.I. Bonner, and M.R. Brann Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain Proc. Natl. Acad. Sci. U. S. A. 83 1986 9827 9831
70. B.Y. Zeng, B. Dass, A. Owen, S. Rose, C. Cannizzaro, B.C. Tel, and P. Jenner Chronic l-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats Neurosci. Lett. 276 1999 71 74